KT has no conflicts of interest to declare. AD is the recipient of grants from Bristol-Myers Squibb, Genentech, Merck, and Roche, as well as consulting fees/honoraria from Merck and Roche. No funding was used in the preparation of this manuscript.
KT performed the acquisition, analysis, and interpretation of data and drafted the manuscript. AD helped to draft the manuscript. KT and AD read and approved the final manuscript.
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.
Selby M, Engelhardt H, Lu L-S, Quigley M, Wang C, Chen B, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 31, 2013(suppl;abstr 3061).
Robert, C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2014. doi: 10.1056/NEJMoa1412082.
Weber JS, Minor D, D’Angelo SP, Hodi FS, Gutzmer R, Bart N, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choicechemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy, Presented at the European Society for Medical Oncology 2014 Congress, Madrid, September 26–30, 2014. 2014. abstract.
Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32(5s).
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
Katy K. Tsai
Adil I. Daud
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II